Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Racemic mixtures: harmless or potentially toxic?

G E Ehrlich1

  • 1University of Pennsylvania, Philadelphia 19106-3731.

American Journal of Hospital Pharmacy
|September 1, 1992
PubMed
Summary

Developing racemic drug mixtures requires evaluating both enantiomers. Each enantiomer has unique properties affecting drug efficacy, safety, and clearance, necessitating individual assessment before marketing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Further studies of platelet rosettes around granulocytes in Behcet's syndrome.

Inflammation·2013
Same author

Fibromyalgia: the plot thickens.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine.

Current medical research and opinion·2008
Same author

The role of COX-2 inhibitors in rheumatoid and osteoarthritis.

Inflammopharmacology·2007
Same author

Symptoms without pathology.

Rheumatology (Oxford, England)·2004
Same author

Concurrence of interphalangeal osteoarthritis and rheumatoid arthritis.

Rheumatology (Oxford, England)·2004

Area of Science:

  • Pharmacology
  • Drug Development
  • Medicinal Chemistry

Background:

  • Racemic drug mixtures contain both active and inactive enantiomers.
  • Enantiomers possess distinct pharmacokinetic and pharmacodynamic profiles.
  • The inactive enantiomer can influence absorption, metabolism, excretion, and receptor binding.

Purpose of the Study:

  • To describe challenges in developing and evaluating racemic drug mixtures.
  • To highlight the importance of understanding individual enantiomer properties.
  • To emphasize the need for comprehensive assessment of each enantiomer's contribution.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic principles for enantiomers.
  • Analysis of potential impacts of inactive enantiomers on drug profiles.
  • Consideration of factors influencing efficacy and toxicity.

Main Results:

  • Racemic mixtures involve administering two distinct drugs.
  • Enantiomers differ in absorption, metabolism, excretion, and receptor affinities.
  • Inactive enantiomers can act as agonists/antagonists, cause adverse effects, or affect clearance.

Conclusions:

  • Thorough determination of each enantiomer's properties is crucial.
  • Differences in enantiomer pharmacokinetics necessitate evaluating their individual contributions to efficacy and toxicity.
  • Market approval requires consideration of whether the racemic mixture offers benefits over a single enantiomer.

Related Experiment Videos